These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 23851493)
1. The immune network in pancreatic cancer development and progression. Wörmann SM; Diakopoulos KN; Lesina M; Algül H Oncogene; 2014 Jun; 33(23):2956-67. PubMed ID: 23851493 [TBL] [Abstract][Full Text] [Related]
2. Macrophages and pancreatic ductal adenocarcinoma. Habtezion A; Edderkaoui M; Pandol SJ Cancer Lett; 2016 Oct; 381(1):211-6. PubMed ID: 26708507 [TBL] [Abstract][Full Text] [Related]
3. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Clark CE; Hingorani SR; Mick R; Combs C; Tuveson DA; Vonderheide RH Cancer Res; 2007 Oct; 67(19):9518-27. PubMed ID: 17909062 [TBL] [Abstract][Full Text] [Related]
4. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Hiraoka N; Yamazaki-Itoh R; Ino Y; Mizuguchi Y; Yamada T; Hirohashi S; Kanai Y Gastroenterology; 2011 Jan; 140(1):310-21. PubMed ID: 20955708 [TBL] [Abstract][Full Text] [Related]
5. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokines in human pancreatic cancer. Roshani R; McCarthy F; Hagemann T Cancer Lett; 2014 Apr; 345(2):157-63. PubMed ID: 23879960 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Alam MS; Gaida MM; Bergmann F; Lasitschka F; Giese T; Giese NA; Hackert T; Hinz U; Hussain SP; Kozlov SV; Ashwell JD Nat Med; 2015 Nov; 21(11):1337-43. PubMed ID: 26479921 [TBL] [Abstract][Full Text] [Related]
8. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Vonderheide RH; Bear AS Front Immunol; 2020; 11():605619. PubMed ID: 33304355 [TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells and their role in pancreatic cancer. Pergamo M; Miller G Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857 [TBL] [Abstract][Full Text] [Related]
11. T-cell programming in pancreatic adenocarcinoma: a review. Seo YD; Pillarisetty VG Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859 [TBL] [Abstract][Full Text] [Related]
12. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Tjomsland V; Niklasson L; Sandström P; Borch K; Druid H; Bratthäll C; Messmer D; Larsson M; Spångeus A Clin Dev Immunol; 2011; 2011():212810. PubMed ID: 22190968 [TBL] [Abstract][Full Text] [Related]
13. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Hartmann N; Giese NA; Giese T; Poschke I; Offringa R; Werner J; Ryschich E Clin Cancer Res; 2014 Jul; 20(13):3422-33. PubMed ID: 24763614 [TBL] [Abstract][Full Text] [Related]
14. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303 [TBL] [Abstract][Full Text] [Related]